Growth Hormone Deficiency (GHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Growth Hormone Deficiency (GHD) is a medical condition that arises due to issues in the pituitary gland, leading to a lack of Growth Hormone (GH) production. This condition is typically observed in children, causing growth failure and short stature. GHD can be categorized into two main types: genetic GH deficiency, which involves identifiable genetic mutations like GH-1, GHRHR, and PROP-1, and idiopathic GH deficiency, where no specific genetic anomaly can be pinpointed. In cases of idiopathic GH deficiency, the pituitary gland is often smaller, and there’s evidence of abnormalities in the pituitary stalk or the posterior lobe being in an abnormal position. The primary indicator of growth hormone deficiency is a deceleration or halt in growth starting around the age of two or three. This concern might emerge through regular growth chart monitoring or become evident when a child joins school and is notably shorter than their peers. Diagnosis of growth hormone deficiency involves blood tests to measure hormone levels and diligent tracking of height using standardized growth charts that compare a child’s height to the average for their age and gender. Severe congenital GHD in infants might not immediately exhibit signs of slow growth; instead, they could mainly present low blood sugar levels. For adults with significant GHD, certain effects might be observed:
1. Redistribution of body fat, leading to increased weight around the waist
2. Reduction in muscle mass and strength
3. Decreased energy levels – Irregularities in cholesterol levels
4. Elevated fracture risk
Individuals affected by GHD undergo treatment with synthetic human GH administered through daily injections prescribed by a medical professional.
• The prevalence of GHD is estimated to be between 1.8 and 2.9 per 10,000 children, with a higher frequency of diagnosis in boys.

Thelansis’s “Growth Hormone Deficiency (GHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Growth Hormone Deficiency (GHD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Growth Hormone Deficiency (GHD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Growth Hormone Deficiency (GHD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Growth Hormone Deficiency (GHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033